Johnson & Johnson (JNJ)vsSandisk Corp (SNDK)
JNJ
Johnson & Johnson
$232.77
-2.48%
HEALTHCARE · Cap: $567.28B
SNDK
Sandisk Corp
$1,559.32
+11.54%
TECHNOLOGY · Cap: $278.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 631% more annual revenue ($96.36B vs $13.18B). SNDK leads profitability with a 34.2% profit margin vs 21.8%. JNJ trades at a lower P/E of 27.3x. SNDK earns a higher WallStSmart Score of 70/100 (B).
JNJ
Buy57
out of 100
Grade: C
SNDK
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.2%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Intrinsic value data unavailable for SNDK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 33 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 70.0%
Revenue surging 251.0% year-over-year
Earnings expanding 618.0% YoY
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Trading at 16.8x book value
Grey zone — moderate risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SNDK
The strongest argument for SNDK centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 34.2% and operating margin at 70.0%. Revenue growth of 251.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SNDK
The primary concerns for SNDK are Price/Book, Altman Z-Score, P/E Ratio. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SNDK is a growth play — different risk/reward profiles.
SNDK is growing revenue faster at 251.0% — sustainability is the question.
SNDK generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SNDK scores higher overall (70/100 vs 57/100), backed by strong 34.2% margins and 251.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Sandisk Corp
TECHNOLOGY · COMPUTER HARDWARE · USA
Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?